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Abstract
The Severe Acute Respiratory Syndrome Coronavirus 2 is a recent disease that originated in China by the end of 2019. The origins of the disease 
can be traced to bats, but it has been transmitted to humans, and the inter-human transmission is particularly rampant which has led to a pan-
demic of unseen proportions.
The organ principally involved is the lungs, and severe pneumonia with lack of oxygen leads to fatalities.
The aim of this review was to study the involvement of the kidneys with regard to COVID-19 infection and how the disease may affect people 
on hemodialysis or those who have undergone a kidney transplant.
Indeed, the virus, in addition to the lungs, may affect other vascularized organs to a common receptor on lung epithelium and the endothe-
lium of any organ.
The kidney, which has a large endothelium surface, is affected, and COVID-19 may lead to acute renal failure.
On the other hand, the virus may easily spread among people who are on hemodialysis three times a week. People on hemodialysis may have 
low immunity, and the virus may have dangerous effects on such people.
Finally, renal transplant patients may be easily affected, and the virus may have severe consequences, even death.
We will summarize the principal prophylactic measures to be adopted and the therapeutic measures available. Clearly due to the recent occur-
rence of the pandemic the majority these measures lack a basis in evidence-based medicine and only highlight the efforts to limit COVID-19 
induced damage.
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Introduction
COVID-19 is a disease caused by the new Coronavirus strain, 
also called Severe Acute Respiratory Syndrome Coronavirus 
2 (SARS-CoV-2). The disease was initially identified in the 
Hubei province of China in late 2019 (1)
There are seven strains of coronavirus that can infect 
humans. Four of them cause a mild respiratory syndrome in 
humans and rarely may cause pneumonia, mainly in immuno-
compromised patients. In the past, two severe epidemics have 
been caused by two different Coronavirus strains: the Severe 
Acute Respiratory Syndrome (SARS-CoV) and the Middle 
East Respiratory Syndrome (MERS-CoV). The mortal-
ity rates for these epidemics were 10 and 37%, respectively 
(2,  3). An in-depth knowledge about these two diseases 
helped us in understanding some of the characteristics of 
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The question remains as to how the COVID-19 virus may 
enter the renal cells. Another study from Varga et al. (14) has 
documented that vascular damage in addition to respiratory 
disease may be observed in the course of COVID-19. Indeed, 
SARS CoV-2 infects the patient binding to the ACE2 recep-
tor, which is expressed both on the pulmonary epithelium 
and on the endothelium of several organs, including the kid-
ney. The endothelium involvement may be the way through 
which the virus enters the cells. Indeed, several studies have 
documented that during the COVID-19 disease, several 
organs may be affected in addition to lungs, such as the myo-
cardium and the kidney (15).
In an observational study, Diao et al. (16) documented 
that, in a retrospective analysis of 85 patients with COVID-
19 infection, confirmed in Wuhan, 23 patients (27.06%) 
exhibited acute renal failure (ARF), principally related to 
tubular necrosis, as histologically documented by Su (13). 
In addition, Diao et al. documented activation of CD68+ 
macrophages together with complement activation. Further 
studies have documented that SARS CoV-2 infection, in 
addition to the release of proinflammatory cytokines, may 
induce ARF by rhabdomyolysis, hypoxemia, and dehydrated 
and microvascular thrombosis related to complement activa-
tion (17, 18) (Figures 1 and 2). Another cause of ARF in 
COVID-19 is associated with the collapsing glomerulopathy 
as documented in two different case reports in which ARF 
associated with heavy proteinuria affected black patients 
(19–21). All the patients were black with an APOL1 high-
risk genotype.
Overall, COVID-19 patients show signs of  renal injury 
including proteinuria (44%), hematuria (26.9%), and 
increased plasma creatinine (15.5%) (22). The presence 
of  virus particles, both in urine and in renal parenchymal 
cells, is probably related to the penetration of  the virus 
through the endothelium and the glomerular barrier (23). 
In another study, Pei et al. (24) documented a renal involve-
ment in 251 out of  333 patients affected by COVID-19. 
Proteinuria was present in 65.8% of  patients and hematuria 
in 41.7%.
The aforementioned study (11) on COVID-19 patients 
hospitalized in New York city documented, during uni-
variate and multivariate logistic regression analyses, the 
risk factors associated with the development of  AKI 
(Table 1).
To date, the exact mechanism of  viral penetration inside 
the kidney and the subsequent renal damage has not been 
completely understood. The binding to ACE2 principally 
in the renal tubules represents the first step (25). The 
transmembrane protease, serine 2 (TMPRSS2), mediates 
this first priming step (26, 27). Once inside the kidney, 
several pathways may be activated as complement activa-
tion, cytokine storm, and interstitial inflammation. Viral 
replication in podocytes could mediate proteinuria (28). 
the SARS-CoV-2. Covid-19 is more contagious than the 
other Coronavirus strains, has the bat as the source of origin, 
and its mode of transmission from bat to man has not been 
completely understood till date. The probability of virus 
transmission between humans is high and could occur via 
droplets, feces or direct contact.
The incubation period is between 1 and 10 days. In the 
vast majority of patients, the disease manifests with a flu-like 
syndrome, but in several patients the COVID disease has a 
more severe manifestation, with onset of fever, cough, myal-
gias, and diarrhea (4). Approximately, 16–20% of patients 
are affected by a severe syndrome, with bilateral pneumonia 
and reduced oxygen saturation requiring admission to the 
intensive care unit (ICU). These patients present with high 
levels of inflammatory cytokines in the blood as interleukin 
(IL)-2, IL-6, IL-7, IL-10, and TNFα (5)
COVID 19 and the kidney
The relationship between COVID-19 and the kidney may be 
divided into three main areas:
1. COVID-19-induced renal disease
2. COVID-19 and dialysis patients
3. COVID-19 and transplant patients
COVID-19-induced renal disease
Although pulmonary infection is the main manifestation in 
the course of COVID-19, other organs, such as the kidney, 
may be of interest as well.
Previous studies of SARS and MERS CoV documented 
the development of acute kidney injury (AKI) in 5–15% of 
patients with a high mortality rate.
Early reports on COVID-19 documented 3–9% of AKI 
in patients with COVID infection (6–8). Other data report 
higher incidence of up to 25% (9).
Two recent reports from New York city noted an incidence 
of AKI in patients hospitalized with COVID-19 at 31% (10) 
and of 36.6% (11) respectively.
One study documented that patients on admission affected 
by leukocyturia, albuminuria, and hematuria, principally 
when associated with low albumin serum concentration 
and low antithrombin III concentration, will easily develop 
AKI (12).
In the renal histopathological analyses of 26 postmortem 
findings of patients with COVID-19 in China, Su et al. (13) 
were able to document renal lesions as proximal tubule 
injury, vacuolar degeneration, and necrosis. By electron 
microscopy, the same authors were able to find Coronavirus 
particles in the tubular epithelium and podocytes. In addi-
tion, an upregulation of angiotensin converting enzyme 2 
(ACE2), the receptor of COVID, was found.
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Figure 1. COVID-19-induced acute kidney injury.
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Figure 2. Coronavirus mechanisms of action and damage to the kidney.
TMPRSS2 = transmembrane protease, serine 2; ACE2 = angiotensin-converting enzyme 2; ATN = acute tubular necrosis; AKI = acute kidney 
injury.
Rhabdomyolysis has also been documented in patients 
with COVID-19 and could contribute to the development 
of  AKI (29).
COVID and dialysis patients
Useful guidelines and suggestions may be obtained from the 
previous epidemics involving the coronavirus, in particular, 
the MERS epidemic.
During such epidemics, useful recommendations have been 
given by the Korean Society of Nephrology (30). According 
to such recommendations, the following key points should be 
followed:
a) Patients on hemodialysis with suspected or confirmed 
MERS-CoV infection should be transferred to a MERS 
clinic or to a hemodialysis center with facilities, such as 
isolation rooms.
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b) If  a patient on hemodialysis is subjected to quarantine 
due to close contact with a confirmed case, the center 
should follow the basic principles provided by the pre-
vention authority.
c) Interhospital transfers should be prohibited.
d) All patients and health care workers should follow the 
standard contact and droplets precautions. A 2-year 
prospective cohort study (31) documented that a strict 
patient surveillance and a proper isolation practice pre-
vented secondary transmission of the virus.
To mitigate the risk of COVID-19 in dialysis facilities, the 
following points have been recently suggested (32):
a) A systemic screening should be adopted for all dialysis 
patients (symptomatic or not).
b) Patients suspected or confirmed to be affected by 
COVID-19 should be isolated.
c) Patients should be instructed on the use of face masks. It 
should be highlighted that controversies on the use and 
type of masks exist according the different organizations 
(33–41).
d) Personnel should be provided with protective equipment, 
including face mask, eye protection, and isolation gowns.
e) Rooms, beds, and dialysis machines should be routinely 
disinfected.
At the beginning of the COVID-19 spread in Europe, the 
European Dialysis (EUDIAL) Working Group of the Euro-
pean Renal Association–European Dialysis and Transplant 
Association (ERA–EDTA) recommended the following 
measures for the prevention, mitigation, and containment 
of the emerging SARS-CoV-2 pandemic in hemodialysis 
 centers (42).
Different sets of recommendations are needed for both the 
healthcare team and the dialysis patients:
a) Recommendations for the health care team:
  The health care team should be trained in the use of 
personal protective equipment.
  The health care team should be aware of possible 
symptoms, so that they can avoid contact with suspected 
persons.
  The health care team should be instructed on the use of 
protective equipment, such as masks (possible FFP2), gog-
gles, mobcap, and disposable surgical gowns and gloves.
b) Recommendations for dialysis patients:
  Patients should be instructed on appropriate hygiene.
  Patients should inform the staff  on their arrival in case 
of suspected symptoms.
  Patients should be instructed to self-isolate.
  Patients’ body temperature should be checked at the 
start and at the end of the dialysis session.
  Symptomatic patients should be dialyzed in an iso-
lated room.
Italy has been deeply affected by the COVID-19 infection, 
especially Northern Italy.
From an overall population of 643 hemodialysis patients 
who reported in four dialysis centers in the province of 
 Brescia (Lombardy region), in March 2020, 94 patients 
(15%) were positive for SARS-CoV-2 RNA.
The data published (43) through univariate analysis and 
noted as significant causes of death were a history of isch-
emic heart disease (0.05), fever (0.005), cough (0.01) and 
shortness of breath at diagnosis (0.001), and elevated C reac-
tive protein (CRP) (0.001). Through multivariate analysis 
significant factors included fever (0.02), cough (0.05), and 
CRP at baseline (43).
Patients’ treatment
The drugs used in the treatment of COVID-19 infection to 
date are:
a) Recombinant soluble ACE2 (44). The rationale behind 
using hrsACE2 is principally its inhibitory effect on pul-
monary infection; however, other organs may also be of 
affected, especially the capillary walls, the heart, and the 
kidney.
b) Antiviral treatment. The use of chloroquine and 
hydroxychloroquine is supported by studies performed 
Table 1. Univariate and multivariate logistic regression anal-
yses of risk factors associated with the development of AKI 
in COVID-19 patients.
Variable Adjusted 
OR
95% CI P
Age (yr) 1.03 1.03–1.04 <0.001
Male 1.14 0.97–1.33 0.10
Diabetes 1.76 1.49–2.07 <0.001
Hypertension 1.25 1.04–1.50 0.02
Cardiovascular 
disease
1.48 1.22–1.80 <0.001
Mechanical 
ventilation
10.7 6.81–16.70 <0.001
Vasoactive 
medication
4.53 2.88–7.13 <0.001
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From a practical point of view, the Brescia patients on dial-
ysis and with COVID-19 infection have been divided into 
three groups:
a) Patients on hemodialysis with low symptoms (fever > 
27.5, cough without dyspnea and without chest X-ray 
indications).
  If  possible treat at home
  Antiviral treatment with lopinavir/ritonavir or 
Darunavir/cobicistat
  Hydroxychloroquine for 5 days
  Antibiotic protection
  No change in dialysis treatment
b) Patients on hemodialysis with severe symptoms 
(fever > 38°, cough, dyspnea, and/or pneumonia X rays 
documented).
  These patients should be admitted in hospital
  Antiviral treatment with lopinavir/ritonavir or 
Darunavir/ritonavir or Darunavir/cobicistat
  Remdesivir should be considered only for patients 
with a rapid clinical deterioration or severe pneumonia
  Hydroxychloroquine
  Antibiotic therapy
  The dialysis treatment should be made in a quaran-
tine area using dialysis membrane with a high cutoff to 
remove middle-sized molecules often responsible for the 
inflammation.
c) Patients hospitalized with clinical deterioration.
  Consider deferring patients to ICU
  Give dexamethasone at a dose of 20 mg/day
  Give Tocilizumab at a dose of 8 mg/Kg of body weight
  Consider plasma therapy if  available.
COVID-19 and renal transplant patients
There is not much data available on COVID-19 infection in 
renal transplant patients, and often they are related to case 
reports (58–60).
Akalin et al. collected data on 36 adult kidney trans-
plant recipients positive for COVID-19 (61) in New York. 
Patients were treated in different ways according to the sever-
ity of their illness. All received reduced immunosuppres-
sive  therapy. Overall, there was a high mortality rate (28% 
at 3 weeks), and all transplanted patients documented a 
more rapid clinical progression than the general population 
affected by COVID-19.
In a different study (62), 10 kidney transplant patients 
tested positive for SARS-CoV-2 by PCR. Among them, three 
patients died (30%) and five developed acute kidney injury 
(AKI) (50%).
Better outcomes were observed at Columbia University 
Hospital, where 15 kidney transplant patients required hos-
pitalization for confirmed COVID-19 (63). Six patients (40%) 
in previous SARS infections. Their efficacy in the treat-
ment of COVID-19 infection seems to be relatively poor 
according to some studies (45, 46). Hydroxychloroquine 
seems to have an improved immunomodulating effect 
and a better pharmacological profile. In a small study, 
hydroxychloroquine, when given in association with anti-
viral agents, shortens the time to reach the polymerase 
chain reaction (PCR) negativization (47).
  However, the use of both chloroquine and hydroxy-
chloroquine is limited by their myocardial toxicity as 
recently documented (48). In a recent study (49), both 
chloroquine and hydroxychloroquine were found to 
have substantial human toxicity, causing myocardial 
depression and vasodilatation with impaired myocardial 
conductivity.
  The antiviral therapy uses second-generation antiret-
roviral drugs in association with lopinavir/ritonavir (50).
  Both lopinavir and ritonavir may lead to myocardial 
toxicity, as they can prolong the QT interval and cause 
Torsade de Pointes (48). A different antiviral associa-
tion is the use of darunavir/ritonavir or darunavir/cobi-
cistat with a similar mechanism of action. The antiviral 
remdesivir is a nucleotide analogue, and its mechanism 
of action is to incorporate itself  in the ribonucleic acid 
(RNA) chain. Several studies have documented its effi-
cacy (51–53).
  Plasma from convalescent patients (54) has been suc-
cessfully used in the treatment of SARS 1 and MERS. 
Preliminary data indicate its usefulness in the treatment 
of SARS-2 as well.
c) Other drugs. One study documented the efficacy of 
azithromycin when given in association with hydroxy-
chloroquine in reducing the time to achieve PCR 
negativization (48).
  Tocilizumab for its efficacy against IL-6 is an 
important drug for patients with a severe cytokine 
storm (55).
  Due to the coagulation activity and its involvement in 
the pathogenesis of the COVID-19-induced lesions, anti-
coagulant drugs, such as heparin, may play an important 
role in the treatment of COVID-19 infection (56).
  The major limitations in documenting the effective 
activity of any of the cited drugs is the lack of controlled 
studies due to the recent occurrence of the disease.
  An emerging problem is the possible mutation of 
the viral genome. In a very recent study on transla-
tional medicine (57), the authors have described eight 
mutations of  SARS-CoV-2 in different continents. The 
virus with mutation in position 14408 was identified in 
Europe in mid-February. The mutation is RNA depen-
dent and RNA polymerase (RdRp), and the new virus 
could be resistant to the antiviral agents acting at that 
level.
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had AKI and four patients required intubation or mechani-
cal ventilation. Two patients died. The authors themselves do 
not understand the reason for this lower mortality rate with 
respect to similar patients in the same area  (61). The small 
patient number does not allow a statistical comparison.
A study from Iran (64) described 12 renal transplant 
patients with COVID-19 infection. In this group, eight 
patients died and four were discharged.
Twenty kidney transplant patients were admitted for SARS-
CoV-2 pneumonia in the Brescia hospital (65): six patients 
developed AKI and five patients (25%) died. The study con-
firms a rapid clinical deterioration in renal transplant patients. 
Transplant patients are at a higher risk of developing a severe 
COVID-19 infection. To reduce this risk, several prophylactic 
and therapeutic measures should be adopted:
a) Prophylaxis. As aforementioned, a careful and repeated 
washing of hands with soap and alcohol is recom-
mended, both for patients and the health care team.
  Vaccinations as antipneumococcal are similarly rec-
ommended to avoid preventable infections.
  Transplant patients should not travel, and the same holds 
good for their partners and family. Lockdown at home is 
recommended in areas with a high rate of COVID-19 
spread.
  Patients should wear a mask covering their mouth and 
nose when venturing out of home, and are recommended 
to stay at a distance from other people. As previously 
mentioned, the frequency of which mask should be used 
is open to wide discussion.
  Prophylactic measures should be particularly adopted 
for patients with mild fever or cough and for those who 
had been in close contact with people suspected to have had 
Covid-19 in the last 14 days (66). In the case of patients with 
symptoms, they should stay in a protected site and should 
follow the guidelines that are continuously updated by the 
Center for Disease Control and Prevention (CDC) (67).
b) Modification of immunosuppressant drugs. Different 
approaches to this very important issue do exist. No all 
are concordant.
  The Descartes Group of the ERA–EDTA (68) sug-
gests the following guidelines:
1) In the case of asymptomatic patients without 
COVID-19 infection, there is no need to modify 
immunosuppressive treatment.
2) In the case of patients with mild disease:
 − If patients are on triple therapy, they should stop 
mycophenolic acid/ azathioprine or mamma-
lian target of rapamycin inhibitors (mTORIs). 
Patients should remain on calcineurin inhibitor 
(CNI) and steroids.
 − If patients are on dual therapy, generally there is 
no need to change, but if  dual therapy is CNI + 
MPA/mTORIs, the latter can be substituted with 
steroids. Reduce calcineurin inhibitors (CNIs) to 
the lowest possible levels considering the immu-
nological risk
3) In the case of patients with COVID-19 pneumonia 
and oxygen saturation over 94–95%:
 − Patients at high risk for age or for co- morbidities, 
such as diabetes, cardiac disease, history of 
smoking, BMI > 30 kg/m2 , estimated glomeru-
lar filtration rate (eGFR) < 30 mL/min, should 
stop MPA/AZA/mTORIs, should stop CNIs and 
increase or start steroids at 15–25 mg/day.
 − High-risk patients should not stop MPA/AZA/
mTORIs, and they should be maintained on dual 
therapy with CNIs and steroids, reducing the 
CNI dosing.
 − In patients on antiviral treatment, CNI should be 
stopped.
4) In the case of patients with severe COVID-19 pneu-
monia, with oxygen saturation under 94% or needing 
mechanical ventilation:
 − All immunosuppressants must be stopped. Ste-
roids should be started or continued at 15–25 
mg/day. CNI might be continued at very low dos-
ing in patients at high risk for rejection
c) Treatment of transplant patients with COVID-19. We 
have already mentioned the drugs used for COVID-19 
infection. The same drugs are used for kidney transplant 
patients with the following considerations (69):
1) Asymptomatic/paucisymptomatic transplant patients 
without dyspnea and with negative chest X rays.
  In addition to the modifications to the immuno-
suppressive treatment, these patients should receive:
  Lopinavir/ritonavir or 
  Darunavir/ritonavir or
  Darunavir/cobicistat
  In addition to the antiviral treatment, they should 
receive:
  Hydroxychloroquine for 5 days at a dose in accor-
dance with the eGFR
  Azithromycin 500 mg/day
2) Patients with severe symptoms with dyspnea and/or 
positive chest X rays.
  These patients should receive the same antiviral 
treatment.
  Remdesivir should be considered as a first-line 
treatment in patients with rapid deterioration, severe 
pneumonia, and needing mechanical ventilation.
  In the case of rapid deterioration, treatment with 
tocilizumab should also be considered. Tocilizumab 
dose should be decided according to body weight (55).
3) Due to the interaction between hydroxychloroquine, 
ritonavir, cobicistat, and the immunosuppressants, 
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patients receiving such antiviral drugs must stop 
mTORIs and CNIs. As hydroxychloroquine is given 
for only 5 days, it is only necessary to check for the 
through levels of CNIs.
d) Renal transplantation from a cadaver or living donor 
during the COVID-19 pandemic. Due to the scarcity 
of data, it is not to date clear as to whether patients on 
waiting list and recent COVID-19 infection may be safely 
transplanted. The general recommendation is that before 
reentering the waiting list, the patient should have two 
PCR negative tests.
  The same recommendation should be made both for 
living and cadaveric donors.
  Even if  the risk has not been verified, RNA viral trans-
mission has been documented in 15% of transplants in a 
study (69).
  The American Society of Transplantation developed 
the following tables (Tables 2 and 3) for a better under-
standing about new transplantations.
  As a consequence, they should be recommended as 
follows:
a) Living donors who have recently travelled to areas 
with high virus spread or who have contacted peo-
ple afflicted with COVID-19 should postpone the 
donation by at least 3 weeks and should have a 
negative PCR.
b) Cadaveric donors affected with COVID-19 must be 
discharged.
c) Cadaveric donors at epidemiological risk for 
COVID-19 should be ruled out for donations that 
are not considered life saving.
d) Living and cadaveric donors with a past history of 
COVID-19 should have been cured at least 1 month 
Table 2. Exposure and clinical screening of potential donors 
with COVID-19.
Epidemiological screening
• Traveled to or residing in an area in the preceding 21 
days, where local COVID-19 transmission is occurring
• Traveled to or from a CDC high-risk area
• Direct contact with known or suspected cases of 
COVID-19 in the preceding 21 days
• Confirmed diagnosis of COVID-19 in the last 28 days
Clinical screening
• Fever (>38°C or subjective fever)
• Malaise or flu-like symptoms ± myalgias
• New cough
• Shortness of breath
• Unexplained abdominal pain, nausea, and/or diarrhea
• Loss of sense of taste and/or smell
Table 3. Donor classification for donor-derived COVID-19 
based on clinical symptoms and epidemiological screening 
of Table 1.
High risk
• Yes to one or more of the epidemiology screening 
criteria PLUS
• Yes to one or more of the clinical screening criteria
Intermediate risk
• Yes, to one or more of the epidemiology screening 
criteria AND
• No or unknown to the clinical screening criteria
Intermediate risk
• No or unknown to the epidemiology screening criteria 
AND
• One or more clinical symptoms without another clear 
diagnosis and in the absence of testing for COVID-19
Low risk
• No epidemiological risk factors AND
• No clinical symptoms
prior to transplantation, and the use of their organs 
should be discussed before transplantation.
The adoption of such measures has reduced the transplan-
tation activity. Preliminary Italian data show a reduction 
of procured organs by about 25% in the first 4 weeks of the 
COVID-19 outbreak (70).
Conclusions
The interrelationship between COVID-19 and the kidneys 
is probably more complex than previously suspected. The 
localization of angiotensin-converting enzyme (ACE)2 
receptor, which is the binding site of  the virus on the epi-
thelial surface, exposes many organs as possible targets of 
COVID-19.
In the case of kidney, several pathways have been identi-
fied, which can lead to acute renal injury. The presence of 
AKI in a patient with severe pulmonary distress may repre-
sent a clear cause leading to death.
A particular condition is represented by the hemodialysis 
patients who may easily be affected by COVID-19 infection, 
either because the virus may easily infect them or because 
they are generally older with reduced immune response.
Renal transplant patients represent a high-risk population 
because they are immunosuppressed.
To date, we do not have enough epidemiological data 
concerning transplant patients, but from the data we have, 
a high predisposition towards AKI or death seems to be 
documented.
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Treatment still represents a crucial problem. The lack of 
evidence-based treatments and of randomized controlled tri-
als makes any possible treatment the object of controversies.
To date, oxygen, lockdown, and protective measures seem 
to be the only safe methods. While waiting for a vaccine or 
the results of controlled trials, we have to carefully monitor 
our patients, and treat them with the available drugs with 
extreme caution.
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